These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 12235267

  • 1. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [Abstract] [Full Text] [Related]

  • 2. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C, Kim RB, Guengerich FP, Wood AJ.
    Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
    [Abstract] [Full Text] [Related]

  • 3. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.
    Cancer Res; 1999 Aug 15; 59(16):3944-8. PubMed ID: 10463589
    [Abstract] [Full Text] [Related]

  • 4. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
    Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, Schinkel AH.
    Mol Pharmacol; 2000 Jan 15; 57(1):188-97. PubMed ID: 10617694
    [Abstract] [Full Text] [Related]

  • 5. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y, Guo X, Lin ET, Benet LZ.
    Drug Metab Dispos; 1998 Apr 15; 26(4):360-6. PubMed ID: 9531525
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
    Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH.
    J Pharmacol Exp Ther; 2001 Jul 15; 298(1):323-30. PubMed ID: 11408558
    [Abstract] [Full Text] [Related]

  • 7. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
    Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M.
    J Pharmacol Exp Ther; 1999 Apr 15; 289(1):149-55. PubMed ID: 10086998
    [Abstract] [Full Text] [Related]

  • 8. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
    Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.
    Drug Metab Dispos; 2001 May 15; 29(5):754-60. PubMed ID: 11302944
    [Abstract] [Full Text] [Related]

  • 9. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
    Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA.
    Br J Cancer; 2002 Sep 09; 87(6):681-6. PubMed ID: 12237780
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M.
    Drug Metab Dispos; 2001 Feb 09; 29(2):145-51. PubMed ID: 11159804
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
    Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G.
    Addict Biol; 2003 Dec 09; 8(4):413-8. PubMed ID: 14690877
    [Abstract] [Full Text] [Related]

  • 12. Several major antiepileptic drugs are substrates for human P-glycoprotein.
    Luna-Tortós C, Fedrowitz M, Löscher W.
    Neuropharmacology; 2008 Dec 09; 55(8):1364-75. PubMed ID: 18824002
    [Abstract] [Full Text] [Related]

  • 13. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
    He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro GM, Cohen LH, Tang W.
    Xenobiotica; 2009 Sep 09; 39(9):687-93. PubMed ID: 19569734
    [Abstract] [Full Text] [Related]

  • 14. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
    Barthomeuf C, Demeule M, Grassi J, Saidkhodjaev A, Beliveau R.
    Planta Med; 2006 Jun 09; 72(7):634-9. PubMed ID: 16739070
    [Abstract] [Full Text] [Related]

  • 15. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T.
    Drug Metab Dispos; 2001 Apr 09; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [Abstract] [Full Text] [Related]

  • 16. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
    Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR.
    Drug Metab Dispos; 2004 Feb 09; 32(2):172-7. PubMed ID: 14744938
    [Abstract] [Full Text] [Related]

  • 17. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
    Chauret N, Tremblay N, Lackman RL, Gauthier JY, Silva JM, Marois J, Yergey JA, Nicoll-Griffith DA.
    Anal Biochem; 1999 Dec 15; 276(2):215-26. PubMed ID: 10603245
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C, Grassi J, Demeule M, Fournier C, Boivin D, Béliveau R.
    Cancer Chemother Pharmacol; 2005 Aug 15; 56(2):173-81. PubMed ID: 15824923
    [Abstract] [Full Text] [Related]

  • 19. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
    Zweers-Zeilmaker WM, Van Miert AS, Horbach GJ, Witkamp RF.
    Res Vet Sci; 1999 Feb 15; 66(1):51-5. PubMed ID: 10088712
    [Abstract] [Full Text] [Related]

  • 20. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
    Gibbs MA, Kunze KL, Howald WN, Thummel KE.
    Drug Metab Dispos; 1999 May 15; 27(5):596-9. PubMed ID: 10220488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.